Meta Healthcare
Pipeline
MedicineMH-101Orphan · FDA

MH-101

Urea cycle disorders

ClinicalStage 4 of 6

A specialised medicine being advanced for adjunctive management in urea cycle disorders, with a US-funded clinical programme and orphan designation in the United States.

Indication
Adjunctive management of hyperammonaemia
Patient population
Paediatric and adolescent patients
Regulatory status
IND active; UK CTA in preparation
Geography
United Kingdom · European Union · United States
Partner status
Wholly owned
Commercial note
Retained UK and EU rights; US development funded.

Milestones

  • US orphan designation granted2024
  • First-in-patient dosing initiated2025

Under clinical evaluation. Not approved for marketing in any territory.

Information on this page describes products and programmes under development or commercialised by Meta Healthcare. Statements about development status and regulatory progress are factual and do not constitute claims of efficacy, superiority or regulatory certainty. Programmes under evaluation are not approved for marketing in all listed territories. Medical nutrition and medical food products should be used under the supervision of a healthcare professional.